Shares of USA-based Intercept Pharmaceuticals (Nasdaq:UCPT) tripled to $275.87 by close of trading on January 9, when the company revealed that a clinical study with obeticholic acid (OCA) for liver disease had been halted on positive results, based on the recommendation of the Data Safety Monitoring Board (DSMB). Intercept Pharmaceuticals Inc (NASDAQ:ICPT) stock opened at $373.00 in last session, and closed at $445.83, while the day range of stock is $373.00 – $497.00. The stock showed a positive weekly performance of 544.54%.
Research analysts at Nomura assumed coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report released on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock opened at $18.31, in last session and closed at $19.15, by gaining 4.70%. The 52 week range of the stock is $8.38 – $19.21. Company’s market capitalization is $1.29 billion.
Clinical-stage biopharmaceutical firm Epizyme Inc (NASDAQ:EPZM) announced good results from a phase 1 study. The market liked what it heard — shares soared almost 97% for the week. Epizyme Inc (NASDAQ:EPZM) stock advanced 8.92% and finished the last session at $40.41. The EPS of the stock remained -5.83. Company’s market capitalization is $1.15 billion.
Trade-Ideas LLC identified Sangamo Biosciences, Inc. (NASDAQ:SGMO) as a “perilous reversal” candidate. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened the session at $18.68, and closed the session at $19.07. The 52 week range of the stock remained $6.75 – $19.40 and the day range was $18.21 – $19.40.